BACKGROUND: We previously showed that the anti-inflammatory drug, sulfasalazine (salicylazosulfapyridine, SASP), can arrest proliferation of MCF-7 and MDA-MB-231 mammary cancer cells by inhibiting uptake of cystine via the x(c-) cystine/glutamate antiporter. Here we examined SASP with regard to reduction of cellular glutathione (GSH) levels and drug efficacy-enhancing ability. METHODS: GSH levels were measured spectrophotometrically. Cellular drug retention was determined with 3H-labeled methotrexate, and drug efficacy with a colony formation assay. RESULTS: Incubation of the mammary cancer cells with SASP (0.3-0.5 mM) led to reduction of their GSH content in a time- and concentration-dependent manner. Similar to MK-571, a multidrug resistance-associated protein inhibitor, SASP increased intracellular accumulation of methotrexate. Preincubation of cells with SASP (0.3 mM) significantly enhanced the potency of the anticancer agent doxorubicin (2.5 nM). CONCLUSIONS: SASP-induced reduction of cellular GSH levels can lead to growth arrest of mammary cancer cells and enhancement of anticancer drug efficacy. Copyright 2007 S. Karger AG, Basel.
BACKGROUND: We previously showed that the anti-inflammatory drug, sulfasalazine (salicylazosulfapyridine, SASP), can arrest proliferation of MCF-7 and MDA-MB-231 mammary cancer cells by inhibiting uptake of cystine via the x(c-) cystine/glutamate antiporter. Here we examined SASP with regard to reduction of cellular glutathione (GSH) levels and drug efficacy-enhancing ability. METHODS:GSH levels were measured spectrophotometrically. Cellular drug retention was determined with 3H-labeled methotrexate, and drug efficacy with a colony formation assay. RESULTS: Incubation of the mammary cancer cells with SASP (0.3-0.5 mM) led to reduction of their GSH content in a time- and concentration-dependent manner. Similar to MK-571, a multidrug resistance-associated protein inhibitor, SASP increased intracellular accumulation of methotrexate. Preincubation of cells with SASP (0.3 mM) significantly enhanced the potency of the anticancer agent doxorubicin (2.5 nM). CONCLUSIONS:SASP-induced reduction of cellular GSH levels can lead to growth arrest of mammary cancer cells and enhancement of anticancer drug efficacy. Copyright 2007 S. Karger AG, Basel.
Authors: Yan Zhang; Hui Tan; Jacob D Daniels; Fereshteh Zandkarimi; Hengrui Liu; Lewis M Brown; Koji Uchida; Owen A O'Connor; Brent R Stockwell Journal: Cell Chem Biol Date: 2019-02-21 Impact factor: 8.116
Authors: L Sleire; B S Skeie; I A Netland; H E Førde; E Dodoo; F Selheim; L Leiss; J I Heggdal; P-H Pedersen; J Wang; P Ø Enger Journal: Oncogene Date: 2015-03-23 Impact factor: 9.867
Authors: Sreenivasulu Chintala; Károly Tóth; Ming-Biao Yin; Arup Bhattacharya; Sylvia B Smith; M Shamsul Ola; Shousong Cao; Farukh A Durrani; Tanjima R Zinia; Rebecca Dean; Harry K Slocum; Youcef M Rustum Journal: Chemotherapy Date: 2010-06-11 Impact factor: 2.544
Authors: Haiquan Lu; Debangshu Samanta; Lisha Xiang; Huimin Zhang; Hongxia Hu; Ivan Chen; John W Bullen; Gregg L Semenza Journal: Proc Natl Acad Sci U S A Date: 2015-07-30 Impact factor: 11.205